Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing

Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…

AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.

UnitedHealthcare to nix nearly two thirds of pediatric prior auths

fiercehealthcare - UnitedHealthcare is set to eliminate close to two-thirds of pediatric prior authorization requirements by the end of the year.

AI Summary: UnitedHealthcare announced a major rollback of pediatric prior authorization requirements, eliminating roughly two‑thirds of those rules to reduce administrative burden and speed care for children. The move aims to ease clinician frustration and patient delays, while insurers and providers brace for workflow and cost‑management implications.